IVT-RNA is set to be a vital tool in future vaccine production, possessing the versatility to be quickly adapted to meet changing requirements such as new variants of viruses. The effectiveness of IVT-RNA was demonstrated in the success of the Covid-19 vaccines, which were built on decades of research.
However, the increasing demands for vaccines produced at scale make reliable quality controls an essential requirement of manufacturing.
In this webinar, we will discuss the capabilities of IVT-RNA vaccines, the diseases that could be protected against, the clinical trials underway showing the most promise, how the market is growing globally, and the indicators of future growth according to GlobalData analysts.
Agilent will also provide expert insight on the best ways to implement quality control measures in IVT-RNA vaccine production and the key devices that can enable this. The company is an internationally respected provider of advanced testing instruments for use in life sciences.
In this webinar, we will explore:
– The potential uses cases for IVT-RNA vaccines
– How IVT-RNA could bring down the costs of producing vaccines
– The advantages of IVT-RNA over other forms of biopharma production
– How to ensure quality control across vaccine manufacturing